Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 2/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.46 |
| ▸ | GLB1 | P16278 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | DRD5 | P21918 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.43 |
| ▸ | EBP | Q15125 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL76763 | 1.00 | GNAI3 (0.46) | GNAI3GNAO1GNAI1GLB1GBA1 | |
| SCHEMBL10130235 | 1.00 | GNAI3 (0.46) | GNAI3GNAO1GNAI1GLB1GBA1 | |
| Fluoride SCHEMBL30330296 | 0.98 | GNAI3 (0.44) | GNAI3GNAO1GNAI1GLB1GBA1 | |
| Hydrochloric Acid SCHEMBL19469324 | 0.98 | GNAI3 (0.48) | GNAI3GNAO1GNAI1GLB1GBA1 | |
| Bromide SCHEMBL2808112 | 0.98 | GNAI3 (0.44) | GNAI3GNAO1GNAI1GLB1GBA1 | |
| Cyanide SCHEMBL30212723 | 0.94 | GNAI3 (0.42) | GNAI3GNAO1GNAI1GLB1GBA1 | |
| SCHEMBL10130526 | 0.94 | GNAO1 (0.53) | GNAI3GNAO1GNAI1HTR1ADRD2 | |
| SCHEMBL14197717 | 0.94 | GNAO1 (0.53) | GNAI3GNAO1GNAI1HTR1ADRD2 | |
| SCHEMBL10130234 | 0.94 | GNAO1 (0.53) | GNAI3GNAO1GNAI1HTR1ADRD2 | |
| SCHEMBL15363082 | 0.92 | GNAO1 (0.56) | GNAI3GNAO1GNAI1HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023150284-A2 | QUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-9040516-B2 | Uracil derivative and use thereof for medical purposes | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140179670-A1 | URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1955697-A1 | 2-AMINOBENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | TRPV1, TRPV2, TRPV5 | GNAI3 567/4885GNAO1 56/4885GNAI1 304/4885 |
| US-20140179670-A1 | URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | URB2, ELANE, NUDT1 | GNAI3 1673/4885GNAO1 641/4885GNAI1 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.